AzTrials
AzTrials

Hemifacial MicrosomiaNCT03861650

Evaluation of Effect of Bone Marrow Aspirate Concentrate on Distracted Mandibular Bone Properties

A study testing Bone Marrow Aspirate Concentrate and Saline in people with Hemifacial Microsomia and Distraction of Bone, run by Yasser Mohamed Nabil Ahmed Khirat El Hadidi.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Maxillofacial Distraction Osteogenesis (DO) has a lot of draw backs; mostly related to long distraction and consolidation time. Rapid rate DO was proposed to decrease the distraction time to avoid consequences of long procedure. Read more about this study

Who is it for?
Ages 6 to 25 years
Conditions the study is for
Hemifacial Microsomia, Distraction of Bone
What is being tested?
Bone Marrow Aspirate Concentrate and Saline
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
12 participants
Where
No sites listed yet
Study dates
30 Dec 2015to 30 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 25 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Patients free from any disease affecting bone formation of both sexes was included in the study.
  • Patients younger than 25 years old.
  • Patients included in the study were post traumatic patients, hemifacial microsomia, Treacher Collins and post ankylotic mandibular deformity.
  • Distraction range was between 15-20 mm.

Who cannot join

  • The presence of uncontrolled systemic disease.
  • Previous radiotherapy on head and neck region.
  • Chemotherapy within the past 12-month period.
  • An active infection at the distraction site.

About this study

Official title: The Effect of Bone Marrow Aspirate Concentrate on Bone Regenerate During Rapid Mandibular Distraction Osteogensis

Maxillofacial Distraction Osteogenesis (DO) has a lot of draw backs; mostly related to long distraction and consolidation time. Rapid rate DO was proposed to decrease the distraction time to avoid consequences of long procedure. The idea of the current study is to provide mesenchymal stem cells (MSCs) in form of Bone Marrow Aspirate Concentrate (BMAC) during rapid distraction to fasten and shorten consolidation. Methods: This trial was conducted on patients requiring mandibular DO. Patients were divided in two groups; control group in which distraction took place at a rate of 1.5 mm /day without any enhancement and study group in which distraction took place at rate of 1.5 mm /day and the distracted bone was enhanced by BMAC

Read the detailed description

Material and Methods:

A prospective case-control trial was conducted on patients requiring mandibular distraction osteogenesis to assess the effect of BMAC on distracted bone quality. Evaluation of newly formed bone quantity and quality was done using a CBCT which was done post distractor removal as a part of routine follow up ( in agreement with European guidelines for the exposure to ionizing radiation) and evaluation of the bone quality was assessed by two examiners to provide interexaminer-reliability.

In order to evaluate the effect of BMAC on bone maturation and possibility of early removal of the distractor; which was not feasible in the clinical study due to the ethical concerns. Mechanical three point bending was applied on distracted mandible after 30 days following distraction to evaluate bone healing and mechanical strength of distracted bone. In addition to histological and radiographic evaluation.

Patients and methods:

Patient grouping and anesthetic technique:

Prospective case-control trial was conducted on patients requiring mandibular distraction osteogenesis. The research was reviewed by the ethical committee of author faculty. Patients were randomly allocated into one of the two groups (To avoid bias, each patient had a number, and this number was picked by the examiners (similar to a deck of shuffled cards) to assign the patient to his/her specific group. Control group (6 patients): control group in which distraction took place at a rate of 1.5 mm /day till planned length was obtained and only saline was injected in defect; based on the assumption that it has no effect on bone healing. Study group in which distraction took place at rate of 1.5 mm /day till planned length was obtained. Distracted bone was enhanced by injection of Bone Marrow Aspirate Concentrate (BMAC).

Anesthesia was induced with IV propofol (Aspen, Ireland), 1.5-2 mg/kg, fentanyl (ADVANZ Pharma, United Kingdom) 1.3 μ/kg and succinyl choline (Aspen, Ireland) 1mg/kg to facilitate nasotracheal intubation using armored tube. Anesthesia was maintained with isoflurane (AbbVie Ltd, United Kingdom) in oxygen and atracurium (Accord-UK Ltd, United Kingdom) in a dose of 0.3-0.6 mg/kg.

BMAC preparation and harvesting:

BMAC was harvested using the Ficoll protocol. Bone marrow was collected the iliac crest using bone marrow trocar. Phosphate buffered saline (PBS) was added to the aspirated bone marrow in a 4:1 ratio. The diluted bone marrow was titrated over Ficoll 400 (BIOCOLL; Biochrom GmbH, Germany), and the solution was centrifuged at a rate of 2,000 rpm for 20 minutes. The buffy layer pellet, which is rich in BMMSCs, was collected using a pipette. The Aspirated BMAC rich with MSCs was added to tissue culture flasks for till day 10 consolidation in DMEM (Thermo Fisher Scientific, United States) and high streptomycin-penicillin concentrate 10,000 U/mL (Sigma-Aldrich, United States); to be stored at -80 0C till injection at day 10 consolidation .

Surgical procedure An intraoal incision was performed similar to bilateral sagittal split osteotomy in the last molar area area to expose the mandibular body. A piezotome was used with copious saline irrigation; to perform the corticotomy to avoid nerve injury. The osteotomy was completed using a chisel and a mallet.

The bi-directional distractor was fixed using four 2.0 extra oral pins. Trial activation and deactivation were performed in operation room to be sure of osteotomy completion before wound closure. A topical antibacterial mouth was used throughout the entire distraction and consolidation period to decrease the risk of infection Postoperative phase and distraction protocol A topical antibacterial mouth was used throughout the entire distraction and consolidation period to decrease the risk of infection. Amoxicillin 875 mg. /clavulanic acid 125 mg (Augmentin, GSK, United Kingdom) capsules twice daily for five days to decrease risk of infection. Ibuprofen 600 mg (Mylan Products Limited, United Kingdom) Tablets twice daily for three days to control pain.

Distraction phase was performed after 5 days of latency. The rate was 1.5 mm per day till the planned chin position was achieved. In the study group, after 10 days of distraction, the prepared BMAC ( the average number of cells was 3 million) were injected in the distraction gap using an 18-gauge needle on days 10 of the consolidation. The control group had no enhancement and was considered as a negative control. The study and control groups underwent 6 months of consolidation after then the distractor pins were removed and CBCT was performed to evaluate the distraction procedure. In addition to the CBCT evaluation of distraction results the distracted bone maturation was evaluated.

Methods of assessment Using the CBCT (iCAT, USA) DICOM files evaluation of bone density was performed (at a fixed exposure value 84 Kv, 4 mA and 12 Sec ) to evaluate bone quality post distraction. Evaluation was done at three points located between pins marks. The first evaluation was done in exact center and other two readings were done 2mm before and 2mm after the central reading in the CT and average was calculated. Two examiners did evaluation to avoid bias and inter examiner reliability was measured to assess accuracy of the measurements

Being tested
Bone Marrow Aspirate Concentrate, Saline
Keywords
bone marrow aspirate concentrate, Hemifacial Microsomia, Distraction osteogenesis
Medical subject headings
Goldenhar Syndrome, Diastasis, Bone

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bone Marrow Aspirate ConcentrateOther

    A rich MSCs prepration made by centrifugation and concentration of aspirated bone marrow

  • SalineOther

    Physiological saline is added in control group to act as placebo

Study groups in NCT03861650
Study groupRoleWhat they receive
Bone Marrow Aspirate ConcentrateExperimentalBone Marrow Aspirate Concentrate is prepared from bone marrow by aspiration by wide bore needle and then prepared by centrifugation to get rich mix of MSCs to improve healing
Receives: Other: Bone Marrow Aspirate Concentrate
SalineSham comparatorSham or placebo drug in the control group
Receives: Other: Saline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assessment of effect of BMAC on rapidly distracted bone quality

    radiographically the bone density was assessed using CBCT of the patients to evaluate the effect of BMAC on bone maturation in term of increased bone density measured in Hounsfield unit as the increase in bone density indicates better healing and more bone maturation and justify addition of BMAC

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2019
  2. Study start30 Dec 2015
  3. Primary completion30 Dec 2018
  4. Study completion30 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Case-control trial
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03861650
Sponsor's protocol ID
392
Status last verified
Mar 2019
First submitted
27 Feb 2019
Last updated
4 Mar 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Bone Marrow Aspirate Concentrate and Saline in people with Hemifacial Microsomia and Distraction of Bone, run by Yasser Mohamed Nabil Ahmed Khirat El Hadidi.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assessment of effect of BMAC on rapidly distracted bone quality (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in